Introduction
Recent long term, high volume, prospective trials have confirmed the efficacy and durability of both Botulinum Toxin-A (BTX-A) and sacral neuromodulation (SNM) in treating idiopathic overactive bladder (OAB) 1, 2 . Despite the mainstream use of both BTX-A and SNM worldwide in treating OAB, the exact mechanisms of action of both treatments are poorly understood. At the ICI-RS meeting in Bristol in 2017, a think tank was convened to answer the question "Do we know the exact working mechanisms of BTX-A and SNM in the treatment of OAB/detrusor overactivity (DO)?" Although the likely answer is 'no', the think tank discussed new mechanisms related to both treatments and tried to correlate modes of action with some clinical perspectives. Finally, we decided to assess urodynamic data before and after these treatments to see if we could glean any further information that could help us understand their mode of action. The think tank discussed future research strategies to help answer the question and advance knowledge, this will be summarised at the end of the manuscript.
Methods
The literature on BTX-A and SNM was reviewed through PubMed searches, restricted to articles published in English. Articles were screened based on titles and abstracts and the most relevant articles included. The focus was related to mechanism of action and urodynamic data.
Pathophysiology of OAB
To understand the effects of SNM and BTX-A in OAB patients, it is important to summarise briefly the proposed pathophysiological mechanisms related to storage symptoms. Several theories, alone or in combination, have been proposed to explain the origin of OAB [3] [4] [5] [6] [7] [8] [9] .
Dysfunction of Afferent Signaling in OAB
OAB may be a result of increased, abnormal afferent activity, resulting in increased reflex efferent signaling. Consequently, voluntary control of micturition is compromised 3 .
Altered Brain Responses
OAB patients present abnormal brain responses in areas processing urge and social propriety 4, 5 .
Alternatively, there might be diminished responses in areas responsible for voluntary voiding.
According to functional magnetic resonance imaging (f-MRI), poor bladder control is specifically associated with inadequate activation of the orbitofrontal cortex.
Myogenic Theory
Partial denervation alters smooth muscle properties, which may result in increased excitability, coordinated myogenic contractions and augmented bladder pressure 6 .
Neurogenic-Myogenic Theory
'Leakage' of Acetylcholine (ACh) from parasympathetic nerves during bladder filling may be related to micromotion of detrusor bundles and afferent activation 7, 8 .
Urothelial Theory
Several compounds (e.g. acetylcholine, ATP, nitric oxide, prostaglandins) are released and/or generated by urothelial cells and are be related to cell signaling events 9 .
BTX-A

Mechanism of action
Chemical transmission and botulinum toxins. Chemical transmission between cells generally
consists of transmitter release from a prejunctional cell, diffusion in the intercellular space and subsequent binding to the cell membrane of a post-junctional cell where it generates a response. Classically this process was described at the neuromuscular junction, where acetylcholine (ACh) released from motor nerves binds to skeletal muscle nicotinic receptors to initiate muscular contraction. However, transmission between any combination of nerves, skeletal/cardiac/smooth muscle, epithelial and other cell types is possible. Transmitters are generally, but not exclusively, stored in prejunctional intracellular vesicles and released when they dock to the cell membrane and exocytose their contents. Docking is achieved by interaction between SNARE proteins located on the cell membrane and vesicles. Botulinum toxins, from Clostridium botulinum bacteria, prevent transmitter release by inhibiting vesicular docking. There are several subtypes (A-G) that cleave different docking proteins. The subtype used most commonly in urological practise, BTX-A, acts on a membrane docking protein SNAP-25. Botulinum toxins are taken into the cell upon binding to a receptor site, SV-2, where they are subsequently cleaved into light and heavy chains so that the former can exert its effect 10 .
OAB and BTX-A. The original rationale for using BTX-A to reduce OAB was the assumption that OAB itself was importantly caused by aberrant release of ACh from parasympathetic efferents to cause DO, in much the same way as antimuscarinic agents were assumed to inhibit the activity of this ACh in detrusor smooth muscle. With human detrusor from overactive bladders ACh and ATP are functional co-transmitters at the nerve-muscle junction, but this would not affect the basic premise as ACh and ATP release were equally attenuated by BTX-A 11 .
Since then the cause of OAB/DO has undergone considerable re-evaluation to also include a myogenic origin of spontaneous activity; a direct control of detrusor contractile function by the overlying mucosa; and augmentation of afferent activity by the mucosa to enhance an afferent-CNS-efferent loop 12, 13 . To accommodate these new theories a greater understanding of the action of BTX-A is needed.
BTX-A and bladder function.
A reduction of maximum detrusor pressure, Pdet, would be expected through any mode of action for BTX-A and has been reported for adults and children with neurogenic or idiopathic DO [14] [15] [16] [17] . However, an increase of compliance has also been reported that implies an additional action in the filling phase 15, 17 . The time course for changes to Pdet and compliance were similar 17 but does not imply a common mode of action. Such changes to Pdet, and compliance were not discernible in a mouse model with intraluminal application of BTX-A (2U/bladder) 18 . The latter study did record a significant reduction of afferent nerve firing on filling that was independent of detrusor pressure during filling or voiding. Furthermore, the attenuation of firing rate was observed in high and low threshold fibres. The study suggested either that nerve excitability itself was reduced by BTX-A and/or the transduction mechanism that links bladder filling to afferent firing had a lower gain.
There is increasing evidence that also supports an effect of BTX-A on purinergic pathways, especially those involved in bladder pathophysiology such as DO 19, 20 . Controversies remain about the origin of the decreased detrusor pressure e.g. inhibition of the exocytosis of ACh versus decreased expression of muscarinic receptors 21, 22 . In a guinea pig model, cleaved SNAP-25 (an indirect marker of a BTX-A effect) products were seen at 24 hours and were expressed in 85% of vesicular ACh Transporter positive cholinergic fibres (parasympathetic) and in 42% and 36% of tyrosine hydroxylase positive adrenergic (sympathetic) and calcitonin gene related peptide positive (sensory) fibres, respectively. This suggested indirectly that the BTX-A mode of action is apparent at both motor and sensory neurones 23 .
BTX-A and urothelial function.
The urothelium has been proposed to provide a vital link between stressors, such as stretch of the bladder wall during filling or exposure to noxious agents, and afferent activation through the release of neuromodulators such as ATP, ACh, nitric oxide (NO) and prostaglandins [24] [25] [26] . Moreover, there is an increase of stressor-induced ATP release in pathologies associated with OAB 27 . This raises the possibility that BTX-A attenuates stretchactivated modulator release and therefore diminishes afferent firing. Such a mechanism could also explain the action of BTX-A to increase bladder compliance, especially when pathologically raised.
ATP release from urothelium is, at least in part via a vesicular route 28, 29 and the molecular apparatus for BTX-A uptake in urothelial cells is present through identification of SV2 and SNAP isoforms 20 . Moreover, BTX-A reduces stretch-activated ATP release from the bladder in vivo 18 , and from urothelial cells in vitro 20, 30 to provide the link between its ability to increase bladder compliance and reduce afferent firing. ACh release from urothelium has been studied less, but is released in greater quantities and more readily than ATP and there is evidence it has a paracrine/autocrine action to regulate urothelial ATP release via an M2 receptor 31 , Figure 1 .
However, release of ACh from urothelial cells in not vesicular 25, 31 , in large part via a CFTR channel and BTX-A has no effect on urothelial ACh release in vitro 31 or in vivo 18 . It is also of interest BTX-A treatment increases NO release from the bladder wall of normal animals 18 , or from urothelial cells of animals with spinal cord injury 30 . As NO is a muscle relaxant its modulation by BTX-A may contribute to its effects on voiding detrusor pressure or filling compliance. The mechanism remains to be characterised.
Overall, changes to in vivo human bladder function after BTX-A administration indicate additional effects to its attenuation of transmitter release from efferent nerves. As more is understood about the neuromodulatory actions of the urothelium so too does the emphasis shift for a major action of BTX-A on the bladder, away from its modulation of vesicular ACh and ATP release at the nervemuscle function to vesicular ATP urothelial release. These data were interpreted that BTX-A significant impaired sensory fibres through a mechanism involving cleavage of SNAP-25 at terminals in the spinal cord dorsal horn 32 . Further evidence supporting central effects was the observation in rats of retrograde transport of BTX-A after bladder injection 33 . BTX-A was radiolabelled with technetium-99 and was detected in the dorsal root ganglia 6 hrs post-injection and corresponding to about 3% of the injected dose into the bladder.
Clinical perspectives on BTX-A that help to understand mechanisms of action
OnabotulinumtoxinA (Botox, Allergan Ltd, Irvine, CA) received a license to treat both neurogenic detrusor overactivity (NDO) at 200 U, secondary to multiple sclerosis and spinal cord injury, and idiopathic OAB at 100 U in 2011 and 2013, respectively. In 2000, Schurch first described the use of BTX-A to treat NDO in spinal cord injured patients, who suffered from urinary incontinence between two intermittent self-catheterisations despite high dosages of anticholinergic drugs 34 .
These patients had a significant reduction of urinary incontinence, with decreased reflex volumes and increased maximum cystometric capacity (MCC). It was believed that the principal mechanism of action in NDO was its effect on efferent parasympathetic pathways. This might be true in part, as during the urodynamic voiding phase post BTX-A treatment reduced Pdetmax and post void residual (PVR) increased. However, urodynamic data also showed a significant increase of maximum cystometric capacity (MCC) and the disappearance of uninhibited bladder contractions, and more importantly patients reported a significant benefit from urgency through their bladder diaries, none of which could be explained by efferent blockade alone. Subsequently a significant reduction in suburothelial P2X3 and TRPV1-positive fibres was demonstrated at 4 weeks after BTX-A, and more significantly at 16 weeks in bladder biopsies from patients suffering from NDO and treated with BTX-A 35 . P2X3 fibre reduction was significantly correlated to attenuation of urgency episodes at 4 and 16 weeks but not to maximum cystometric capacity or detrusor pressures, with a similar trend for TRPV1, suggesting a sensory mechanism.
Repeated BTX-A injections are required as effects diminish, but are equally efficacious in OAB and NDO with mean duration of effect of 7.6 and 9.0 months, respectively for 100 and 200 U 1, 36 .
Seroconversion, the presence of toxin neutralising antibodies, was very low but dose-dependent; 0.4% for 150 U in OAB 1 and 1.5% for 200 U in NDO 36 . In seroconverted patients their request for further injections was sooner than those that had not seroconverted (4.9 vs 9.1 months) 36 .
Sacral Neuromodulation (SNM)
SNM is an established alternative for treatment of overactive bladder symptoms in patients who failed previous therapies. Although its mechanism of action is not completely understood, several studies have demonstrated its efficacy and durability 2, 37, 38 . Continuous improvements have been introduced and it is now a minimally invasive technique, performed under local anesthesia, and might be considered before invasive reconstructive procedures. Briefly, an electrode is implanted in the S3 foramen and connected to an implantable pulse generator (IPG). The patient undergoes a test phase lasting for days to weeks to determine whether SNM has provided a relevant benefit.
If results are positive, the IPG is implanted in the upper buttocks 39 . At present, InterStim® Therapy (Medtronic, Minneapolis, MN, USA) is licensed for treatment of chronic non-obstructive urinary retention and symptoms of OAB, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, or in patients with idiopathic lower urinary tract dysfunction who have failed or could not tolerate more conservative treatments 40 .
SNM Mechanism of Action
The goal of SNM is to modulate abnormal sensations and involuntary reflexes of the lower urinary tract and restore voluntary control. SNM therapeutic benefits may arise from the effects of electrical stimulation on afferent and efferent nerve fibres connecting the pelvic viscera, and spinal interneurons to the central nervous system. SNM influences sacral afferents and modulates spinal cord reflexes and brain centres involved in lower urinary tract function 37 . Thus, patients whose neural system is not intact may not be ideal candidates for this therapy 41 .
The stimulator provides an electrical charge to an area near the sacral nerve, resulting in altered neural activity. This stimulation depolarises the nerve, generating an action potential which propagates along the axon. SNM electrically stimulates somatic afferent nerves in a sacral spinal root and sends signals to the CNS that may restore normal bladder function. Activation of somatic afferent nerves inhibits bladder sensory pathways and reflex bladder hyperactivity 3 . Unlike other therapies that target the bladder directly, this approach does not directly influence the bladder or sphincter muscles 42, 43 . The maximal effect of neuromodulation is not directly attained, indicating that neuromodulation induces adaptive changes (i.e. neural plasticity). This could be caused by negative modulation of excitatory synapses in the central micturition reflex pathway 42 . Evidence from cats suggests that reduction of bladder activity occurs primarily in the CNS by inhibition of the ascending or descending pathways of the spinobulbospinal micturition reflex 44 . However, experiments show that SNM delivers graded responses dependent on stimulus protocols [45] [46] [47] . The inhibitory effects on bladder contraction may be mediated by both afferent and efferent mechanisms. Lower intensities of stimulation may activate large, fast-conducting fibres acting through the afferent limb of the micturition reflex arc in SNM. Higher intensities may additionally act through the efferent limb 45 .
The effects of acute electrical stimulation frequency and amplitude on the dorsal nerve of the penis (DNP), pudendal nerve (PN) and S1 sacral nerve on isovolumetric reflex bladder contractions and maximum cystometric capacity was studied in anaesthetised cats 46 . There was no significant difference in the maximum extent to which the optimised frequency or amplitude inhibited bladder contractions or increased cystometric capacity. However, the range of amplitudes and frequencies for maximum inhibition was larger for DNP stimulation than for PN or S1 stimulation 46 .
Three rate-setting sequences have been tested in OAB female patients undergoing SNM: 5.2, 14 and 25 Hz 47 . There were significant effects on the number of incontinence episodes and pad changes per day. At 5.2 Hz there were more incontinence episodes and pad changes than at 14 or 25 Hz. The number of adverse events was similar across the three rate settings, but programming-related adverse events were lowest in the 14 Hz group 47 .
Can we gain valuable information on the mechanism of action of BTX-A and SNS from urodynamic or other tests?
Patient selection is a key factor in achieving optimal clinical outcomes with BTX-A and SNM.
Clinical factors, such as severity of urge incontinence episodes, age, and comorbidity may help to guide treatment choice 48, 49 . However, improving our understanding their mechanism of action may provide a more satisfactory way to guide patient selection, and urodynamic studies may prove valuable in this regard in identifying predictive factors for success and complications.
BTX-A. Results on the effect of intravesical injections of BTX-A on urodynamic variables supports
the hypothesis that it has both afferent and efferent mechanisms of action in OAB. A randomised placebo-controlled study in idiopathic OAB showed a dose-dependent improvement of mean cystometric capacity, with 100 U leading to a mean improvement by 71 ml at 12-week follow-up 50 .
Improvements in the mean volume at first involuntary detrusor contraction by 83 ml with 100 U also confirm its effect on the afferent micturition pathway. A systematic review of studies also showd consistent improvements in filling-phase parameters of mean maximum cystometric capacity and maximum detrusor pressure following BTX-A injection of 32% and -31%, respectively 51 . The presence or absence of DO has been shown in several studies not to influence the outcome as assessed by patient-reported outcome measures. However, this may be due to limitations in assessment, as these studies were based on standard cystometry which itself has a poor negative predictive value in diagnosing DO 52 . To more accurately determine whether the presence and severity of DO is a predictor of poor outcome, future studies should be undertaken using ambulatory urodynamics.
Urodynamic findings pre-and post-injection in five patients who did not respond to BTX-A injections for idiopathic DO habe been reviewed 53 . Baseline maximum detrusor pressure during filling of greater than 110 cmH2O had a sensitivity and specificity of 86% and 100%, respectively, in predicting a poor response to treatment. However, future study in a larger cohort of patients is warranted to validate these findings. The effect of BTX-A on voiding urodynamic parameters have not been well-studied in large randomised-controlled trials. However the urodynamic voiding parameters in 67 patients treated with 200U of BTX-A have been reviewed and it was found that patients requiring clean intermittent self-catheterisation (CISC) had a lower baseline Qmax and detrusor contractility 54 . A projected isovolumetric pressure (PIP1) of ≤50 cmH2O in women (sensitivity 83%; specificity 70%) and bladder contractility index (BCI) ≤120 in men (sensitivity 70%; specificity 79%) predicted the need for CISC. More recently, the outcomes of 290 patients treated with BTX-A for OAB have been reviewed, where it was found that a voiding efficiency of <89% ((voided volume/total bladder capacity) X100) was a predictor of a high postvoid residual (>200 ml) 55 . However, these studies were limited by their sample size and retrospective nature. Larger prospective studies of filling and voiding parameters are required to identify predictive factors for poor outcomes and the need for CISC, to aid patient counselling and selection.
An alternative drug delivery technique using BTX-A encapsulated in liposomes has been trialled in a double-blind randomised-controlled trial, with significant improvements in frequency and urgency and no increased risk of urinary retention compared to placebo 56 . Urodynamic variables were not assessed in this study but in a preliminary animal study a significant reduction in inter-contraction interval was measured, with no effect on voiding detrusor contraction strength suggesting an afferent effect without significant efferent response 57 . Further studies of alternative drug delivery techniques (liposomes/electromotive drug administration) should include a urodynamic assessment of storage and voiding function.
SNS.
A study analysing pre and post-operative urodynamic findings in 33 women with IDO reported improvements in filling-phase parameters of median maximum detrusor pressure (29% reduction), median amplitude of the highest involuntary detrusor contraction (24% reduction), and maximum cystometric capacity (33% improvement) at 6 months after implantation 58 . However, effects on the voiding parameters of urethral resistance and bladder contraction strength were not significantly different compared to baseline. This may suggest that SNM does not have a direct role in the efferent arm of the micturition reflex, and rather affects voiding function through a different, possibly central, mechanism. This has also been suggested by neurophysiological studies using EEG recordings during SNM by S3 stimulation, which showed increased activity in the sensory cortex 59 .
Another study of 19 women who underwent SNM for OAB highlighted a potential role for urethral function in its mode of action 60 . Urethral instability (defined as urethral pressure variations of more than 15 cmH20) disappeared in 54% of successfully treated patients, a change that was not seen for DO. Furthermore, 84% of patients had urethral pressure fluctuations of >30 cmH20 prior to treatment, but this was seen in only 29% following implantation. Again, significant improvements were seen in mean volume at first sensation (from 98 ms to 235 ml) and mean peak detrusor pressure during filling (from 42 cmH20 to 25 cmH20), and has been confirmed by others 61 . Another study of 54 patients confirmed the effects of SNM on filling-phase parameters, with improvements in mean bladder volume at first sensation by 57% and maximum cystometric capacity by 29%. As is the case with studies on BTX-A, the presence of DO has no influence on the clinical success of SNM 62 . These findings have been confirmed in other studies with similar magnitudes of effect 63 .
When ambulatory urodynamics were assessed before and after SNM, there was no significant difference in the maximum amplitude of detrusor contraction or number of detrusor contractions, but the detrusor activity index (DAI) correlated significantly with clinical success 64 .
The use of neurophysiological testing of somatosensory evoked potentials (SEP's) of the pudendal and posterior tibial nerves has shown that the mechanism of action of SNM is via afferent pathways at the cortical level, and preliminary evidence suggests that the pattern of SEP and its modification by SNM could be used as a predictive factor of successful clinical outcome 65 . This promising finding needs to be reproduced to determine its clinical utility.
Conclusions
The exact working mechanisms of BTX-A and SNM are complicated and are currently not fully known, but a considerable amount of research has yielded information about potential mechanisms. BTX-A appears to have both motor and sensory effects as seen in clinical practice and further evidenced by urodynamic data, human biopsy work and animal models. SNM is likely to modulate abnormal sensory signaling and to correct any imbalance seen between sensory and motor signaling related to the bladder. Further research into the working mechanisms of these treatments will help us further understand the working mechanisms of BTX-A and SNM but also provide further insights into the pathophysiology of OAB. • Can combination of SNM and pharmacotherapy (e.g. antimuscarinics, mirabegron, opioids) increase efficacy?
Research Proposals
BTX
• What is the onset/offset of action in SNM?
• Alteration of stimulation parametersfrequency, cycling and impact on efficacy are needed to answer the following questions: do they correlate with clinical outcome? Can they be used as predictive factors? Can they help determine optimal stimulation parameters for SNM
